menu
    • menu
    [{"orgOrder":0,"company":"Teikoku Pharma USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Teikoku Pharma USA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Teikoku Pharma USA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Teikoku Pharma USA \/ Not Applicable"},{"orgOrder":0,"company":"Teikoku Pharma USA","sponsor":"Link Healthcare Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lidocaine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Teikoku Pharma USA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Teikoku Pharma USA \/ Link Healthcare Group","highestDevelopmentStatusID":"12","companyTruncated":"Teikoku Pharma USA \/ Link Healthcare Group"}]

    Find Clinical Drug Pipeline Developments & Deals by Teikoku Pharma USA

    Menu

    Teikoku Pharma USA

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Teikoku Pharma USA

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Teikoku Pharma USA

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Link Healthcare Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Teikoku Pharma USA, Inc. Announces NMPA Approved Lidoderm® in China on May 8, 2024

                            Details : NMPA has approved Lidoderm® ("lidocaine 5% patch as lidocaine cataplasms") a local anesthetic for the treatment of Post Herpetic Neuralgia in China.

                            Brand Name : Lidoderm

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 30, 2024

                            Lead Product(s) : Lidocaine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Link Healthcare Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Teikoku Pharma USA

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Teikoku Pharma USA

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexmedetomidine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Teikoku Pharma Granted FDA Fast Track Designation for TPU-006, a Novel 4-day Dexmedetomidine Transdermal Syste...

                            Details : TPU-006 is an investigational transdermal system that delivers dexmedetomidine, a selective α2-adrenergic agonist, for up to four days from a single application, which is investigated for the treatment of Post Operative Pain.

                            Brand Name : TPU-006

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 21, 2023

                            Lead Product(s) : Dexmedetomidine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth